Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma

Sorafenib, an oral multikinase inhibitor of Raf, VEGF and PDGF receptor signaling is approved for advanced hepatocellular carcinoma (HCC). One strategy to improve HCC therapy is to combine agents that target key signaling pathways. Aberrant mesenchymal-epithelial transition factor (c-Met) activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xiufeng, Feng, Kang, Zhang, Ye, Li, Zengyao, Zhou, Fan, Dou, Huiqiang, Wang, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494942/
https://www.ncbi.nlm.nih.gov/pubmed/25895026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494942/
https://www.ncbi.nlm.nih.gov/pubmed/25895026

Ejemplares similares